Tag: Hemostemix

January 2, 2020

Hemostemix Announces Private Placement for Up to C$3 Million

Hemostemix announced a non-brokered private placement of up to 300,000,000 units at C$0.01 a piece for gross proceeds of up...
April 9, 2019

Hemostemix Reaches Milestone in the ACP-01 Phase 2 Critical Limb Ischemia Clinical Trial

Hemostemix (TSXV:HEM, OTCQB:HMTXF) has announced an enrollment milestone in its continuing Phase 2 clinical trial for critical limb ischemia (CLI)....
February 25, 2019

Hemostemix Announces UC Davis Health Added as a Trial Site for Phase II Clinical Trial

Hemostemix (TSXV:HEM, OTCQB:HMTXF) has announced it has received all its approvals from UC Davis Health to be the location for...
November 9, 2018

Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01

Hemostemix (TSXV:HEM; OTCQB:HMTXF) is pleased to provide the following update on its research and development activities. As quoted in the press...
October 30, 2018

Hemostemix Announces OTCQB Listing and DTC Eligibility

Hemostemix (TSXV:HEM; OTCQB:HMTXF) is pleased to announce the Company has been approved for up-listing its common shares for trading on...
October 9, 2018

Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial

Hemostemix (TSXV:HEM) is pleased to announce that it has received all approvals from three new medical centers to be clinical trial...
July 18, 2018

Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial

Hemostemix (TSXV:HEM) has announced it has treated three additional patients including its first two patients in the US under its...